The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA Pediatrics. Heidi L. Moline, MD, MPH, ...

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic—an effective antiviral that ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

This story was originally published by Healthbeat. Sign up for their public health newsletters at healthbeat.org/newsletters.

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in pediatric ICU utilization.

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...